Nanoencapsulation of Ferrocene Incorporated Thiourea and Doxorubicin for Treatment of Acute Myeloid Leukemia /
Nimra Idrees
- 102p. Soft Copy 30cm
Acute myeloid leukaemia (AML) is a type of hematologic malignancy that is distinguished by a malfunction in stem cell differentiation, which results in an accumulation of immature cells in the bone marrow and peripheral circulation. Individuals with AML require constant monitoring and novel treatment options; thus, the condition is viewed as a severe problem in the health system. The International Agency for Research on Cancer (IARC) has classified benzene as a category I carcinogen since 1987. According to the findings, benzene causes acute myeloid leukaemia (AML) and acute non-lymphocytic leukaemia (ANL). Doxorubicin (DOX) is a common first-line treatment for many malignancies. However, its therapeutic efficacy is restricted by undesired side effects such as gonadotoxicity, cardiotoxicity, and renal toxicity. The nonspecific action, poor distribution, and limited solubility of DOX are some of its drawbacks. Ferrocenyl compounds with amide or amine moieties were found to be anticancer in the lymphocytic leukaemia P-388. The activity of ferrocene integrated thiourea can be seen by focussing on the DNA, topoisomerase II, and cell membrane. They bind to DNA with great affinity via covalent or non-covalent bonds. Intercalation, groove binding, and electrostatic forces are commonly used to damage or break DNA. DNA damage causes cell cycle arrest, which leads to apoptosis and irreversible damage to the cell genome. Drug-resistant cancer cells and chemotherapeutic medicines with insufficient stability and solubility for optimal efficacy at the target location are two major difficulties in conventional cancer treatment. Liposomal nanoparticles were created for ferrocene-incorporated thiourea drug (FITU), DOX, and their combination to test their activity against benzene-induced acute myeloid leukaemia (AML) in wistar rats, and their free drug activity was compared. Before undertaking in-vivo testing, the developed nanoparticles were characterised and evaluated in-vitro. Liposomal nanoparticles outperformed free drug in terms of reduced adverse effects and higher bioavailability due to tailored distribution via liposomal nanoparticles